ヘリコバクター・ピロリ感染症(Helicobacter Pylori Infections)の治療薬パイプライン動向(2015年上半期版)

【英語タイトル】Helicobacter Pylori Infections - Pipeline Review, H1 2015

Global Markets Directが出版した調査資料(GMDHC6065IDB)・商品コード:GMDHC6065IDB
・発行会社(調査会社):Global Markets Direct
・発行日:2015年1月22日
・ページ数:68
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・調査対象地域:グローバル
・産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD2,000 ⇒換算¥216,000見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD4,000 ⇒換算¥432,000見積依頼/購入/質問フォーム
Global Site License(複数国内共有可)USD6,000 ⇒換算¥648,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
当調査レポートでは、世界におけるヘリコバクター・ピロリ感染症(Helicobacter Pylori Infections)の治療薬開発パイプライン動向について調査・分析し、企業で開発中の治療薬、大学/研究機関で研究中の治療薬、後期段階の製品、治験段階の製品、初期段階の製品、単剤治療薬/併用治療薬/標的別/作用機序別/投与経路別/分子の種類別治療薬の評価、各薬剤のプロファイル(説明、作用機序、研究開発の進展状況)などのデータをお届けいたします。

・イントロダクション
・ヘリコバクター・ピロリ感染症(Helicobacter Pylori Infections)の概要
・ヘリコバクター・ピロリ感染症(Helicobacter Pylori Infections)治療薬の開発
  - パイプライン製品の概要
  - パイプライン製品の比較分析
・企業で開発中の治療薬
・大学/研究機関で研究中の治療薬
・ヘリコバクター・ピロリ感染症(Helicobacter Pylori Infections)パイプライン製品の概略
  - 後期段階の製品
  - 治験段階の製品
  - 初期段階の製品
・製品
・大学/研究機関別、研究中の製品
・ヘリコバクター・ピロリ感染症(Helicobacter Pylori Infections)治療薬開発に取り組んでいる企業:企業別製品パイプライン
・ヘリコバクター・ピロリ感染症(Helicobacter Pylori Infections)治療薬の評価
  - 単剤治療薬
  - 併用治療薬
  - 標的別
  - 作用機序(MoA)別
  - 投与経路(RoA)別
  - 分子の種類別
・各薬剤のプロファイル:説明、作用機序、研究開発(R&D)の進展状況
・パイプライン製品の最新動向
・開発休止中の製品/プロジェクト
・開発が中止された製品
・製品開発のマイルストーン
【レポートの概要】

Helicobacter Pylori Infections – Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Helicobacter Pylori Infections – Pipeline Review, H1 2015’, provides an overview of the Helicobacter Pylori Infections’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Helicobacter Pylori Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Helicobacter Pylori Infections and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Helicobacter Pylori Infections
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Helicobacter Pylori Infections and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Helicobacter Pylori Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Helicobacter Pylori Infections pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Helicobacter Pylori Infections
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Helicobacter Pylori Infections pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

【レポートの目次】

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Helicobacter Pylori Infections Overview 7
Therapeutics Development 8
Pipeline Products for Helicobacter Pylori Infections – Overview 8
Pipeline Products for Helicobacter Pylori Infections – Comparative Analysis 9
Helicobacter Pylori Infections – Therapeutics under Development by Companies 10
Helicobacter Pylori Infections – Therapeutics under Investigation by Universities/Institutes 11
Helicobacter Pylori Infections – Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Early Stage Products 14
Helicobacter Pylori Infections – Products under Development by Companies 15
Helicobacter Pylori Infections – Products under Investigation by Universities/Institutes 16
Helicobacter Pylori Infections – Companies Involved in Therapeutics Development 17
Daewoong Pharmaceutical Co., Ltd. 17
EpiVax, Inc. 18
ImevaX GmbH 19
ImmunoBiology Ltd. 20
RedHill Biopharma Ltd. 21
Sequella, Inc. 22
Shanghai Zerun Biotechnology Co., Ltd. 23
Sigmoid Pharma Limited 24
Takeda Pharmaceutical Company Limited 25
Helicobacter Pylori Infections – Therapeutics Assessment 26
Assessment by Monotherapy Products 26
Assessment by Combination Products 27
Assessment by Target 28
Assessment by Mechanism of Action 30
Assessment by Route of Administration 32
Assessment by Molecule Type 34
Drug Profiles 36
(rifabutin + amoxicillin sodium + omeprazole) – Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
DWJ-1325 – Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
H.pylori vaccine – Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
helicobacter pylori infection vaccine – Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
helicobacter pylori vaccine – Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
helicobacter pylori vaccine – Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
helicobacter pylori vaccine [Hel-305] (multivalent) – Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
HPi-1 – Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
IMX-101 – Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Small Molecules for Helicobacter Pylori Infections – Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Small Molecules to Inhibit DNA Synthesis for Infectious Diseases – Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
SQ-109 – Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
vonoprazan – Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
Helicobacter Pylori Infections – Recent Pipeline Updates 53
Helicobacter Pylori Infections – Dormant Projects 57
Helicobacter Pylori Infections – Product Development Milestones 58
Featured News & Press Releases 58
Dec 26, 2014: New Drug Application Approval of TAKECAB for the treatment of Acid-related Diseases in Japan 58
Nov 10, 2014: FDA Grants QIDP Fast-Track Designation To RedHill Biopharma’s Phase 3 H. Pylori Drug RHB-105 58
Aug 27, 2014: RedHill Biopharma Provides Update on Expansion of Ongoing RHB-105 Phase III Study, Targeting Broadened H. pylori Indication Authorized by FDA 59
Dec 23, 2013: RedHill Biopharma Reports Positive PK Results in Support of Ongoing RHB-105 Phase III H. pylori Study 61
Dec 17, 2013: RedHill Biopharma Announces First Patients Dosed in Phase III Study of RHB-105 for H. pylori Infection 62
Dec 02, 2013: ProJect Pharmaceutics and TUM-Spin-off ImevaX Announce Agreement on Development of Pharmaceutical Formulation for IMX101 63
Oct 30, 2013: RedHill Biopharma Initiates Phase III Study of RHB-105 for H. pylori Infection 64
Oct 22, 2013: RedHill Biopharma Announces FDA Acceptance of IND Application for RHB-105 Phase III Study – to Commence Shortly 65
Dec 06, 2010: Sequella Wins FDA Approval To Begin Phase II Trial Of SQ109 In Helicobacter pylori-Associated Duodenal Ulcers 66
Appendix 67
Methodology 67
Coverage 67
Secondary Research 67
Primary Research 67
Expert Panel Validation 67
Contact Us 68
Disclaimer 68

[List of Tables]
Number of Products under Development for Helicobacter Pylori Infections, H1 2015 8
Number of Products under Development for Helicobacter Pylori Infections - Comparative Analysis, H1 2015 9
Number of Products under Development by Companies, H1 2015 10
Number of Products under Investigation by Universities/Institutes, H1 2015 11
Comparative Analysis by Late Stage Development, H1 2015 12
Comparative Analysis by Clinical Stage Development, H1 2015 13
Comparative Analysis by Early Stage Development, H1 2015 14
Products under Development by Companies, H1 2015 15
Products under Investigation by Universities/Institutes, H1 2015 16
Helicobacter Pylori Infections - Pipeline by Daewoong Pharmaceutical Co., Ltd., H1 2015 17
Helicobacter Pylori Infections - Pipeline by EpiVax, Inc., H1 2015 18
Helicobacter Pylori Infections - Pipeline by ImevaX GmbH, H1 2015 19
Helicobacter Pylori Infections - Pipeline by ImmunoBiology Ltd., H1 2015 20
Helicobacter Pylori Infections - Pipeline by RedHill Biopharma Ltd., H1 2015 21
Helicobacter Pylori Infections - Pipeline by Sequella, Inc., H1 2015 22
Helicobacter Pylori Infections - Pipeline by Shanghai Zerun Biotechnology Co., Ltd., H1 2015 23
Helicobacter Pylori Infections - Pipeline by Sigmoid Pharma Limited, H1 2015 24
Helicobacter Pylori Infections - Pipeline by Takeda Pharmaceutical Company Limited, H1 2015 25
Assessment by Monotherapy Products, H1 2015 26
Assessment by Combination Products, H1 2015 27
Number of Products by Stage and Target, H1 2015 29
Number of Products by Stage and Mechanism of Action, H1 2015 31
Number of Products by Stage and Route of Administration, H1 2015 33
Number of Products by Stage and Molecule Type, H1 2015 35
Helicobacter Pylori Infections Therapeutics - Recent Pipeline Updates, H1 2015 53
Helicobacter Pylori Infections - Dormant Projects, H1 2015 57

[List of Figures]
Number of Products under Development for Helicobacter Pylori Infections, H1 2015 8
Number of Products under Development for Helicobacter Pylori Infections - Comparative Analysis, H1 2015 9
Number of Products under Development by Companies, H1 2015 10
Comparative Analysis by Early Stage Products, H1 2015 14
Assessment by Monotherapy Products, H1 2015 26
Number of Products by Top 10 Targets, H1 2015 28
Number of Products by Stage and Top 10 Targets, H1 2015 29
Number of Products by Top 10 Mechanism of Actions, H1 2015 30
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 31
Number of Products by Top 10 Routes of Administration, H1 2015 32
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 33
Number of Products by Top 10 Molecule Types, H1 2015 34
Number of Products by Stage and Top 10 Molecule Types, H1 2015 35

【掲載企業】

Daewoong Pharmaceutical Co., Ltd.
EpiVax, Inc.
ImevaX GmbH
ImmunoBiology Ltd.
RedHill Biopharma Ltd.
Sequella, Inc.
Shanghai Zerun Biotechnology Co., Ltd.
Sigmoid Pharma Limited
Takeda Pharmaceutical Company Limited

★調査レポート[ヘリコバクター・ピロリ感染症(Helicobacter Pylori Infections)の治療薬パイプライン動向(2015年上半期版)] (コード:GMDHC6065IDB)販売に関する免責事項を必ずご確認ください。
★調査レポート[ヘリコバクター・ピロリ感染症(Helicobacter Pylori Infections)の治療薬パイプライン動向(2015年上半期版)]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆